Research programme: anti-grass pollen allergy antibodies - Mabylon
Latest Information Update: 19 Sep 2024
At a glance
- Originator Mabylon
- Class Antiallergics; Antibodies; Plant allergy immunotherapies
- Mechanism of Action Immunosuppressants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Grass pollen hypersensitivity
Most Recent Events
- 09 Sep 2024 Research programme: anti-grass pollen allergy antibodies - Mabylon is available for licensing as of 09 Sep 2024. https://www.mabylon.com/en/Partnering.htm
- 09 Sep 2024 Preclinical trials in Grass pollen hypersensitivity in Switzerland (Parenteral), prior to September 2024 (Mabylon pipeline, September 2024)